AbbVie Fights FTC's Quick Appeal Bid In Pay-For-Delay Case
The Federal Trade Commission should be denied partial final judgment on a ruling that gutted a pay-for-delay suit against AbbVie Inc. over testosterone drug AndroGel, because the agency would not suffer...To view the full article, register now.
Already a subscriber? Click here to view full article